By Gina Shaw
Empiric antibiotic coverage for methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in patients with diabetic foot infections (DFI) did not correlate with risk factors for these organisms, according to data presented at the ASHP Midyear 2024 Clinical Meeting & Exhibition, in New Orleans (poster 8-041).
Broad-spectrum antibiotics are often used empirically for diabetic foot. “For example, vancomycin is occasionally added to regimens without regard